ITabMed develops antibody-based immunotherapies for hematopoietic and solid cancers.
Tianweiyuan and Biomedicine (Shanghai) Co., Ltd., doing business as ITabMed Ltd., develops tumor immunotherapies for blood cancers and solid tumors. Its iTAb™ platform uses T cell engager technology; its A-319 and A-337 products were in phase I clinical development. Founded in 2020 as a spin-off from Generon BioMed Ltd, the company is based in Shanghai, China. In December 2021, it raised USD 20 million in Series A funding co-led by 3E Bioventures Capital and Regent Capital, with BINHAI Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Tianweiyuan and Biomedicine (Shanghai) Co., Ltd.? This is my company